These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 16751064)

  • 1. VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.
    Brazelle WD; Shi W; Siemann DW
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(3):836-41. PubMed ID: 16751064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
    Williams KJ; Telfer BA; Brave S; Kendrew J; Whittaker L; Stratford IJ; Wedge SR
    Clin Cancer Res; 2004 Dec; 10(24):8587-93. PubMed ID: 15623642
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
    Gustafson DL; Frederick B; Merz AL; Raben D
    Cancer Chemother Pharmacol; 2008 Feb; 61(2):179-88. PubMed ID: 17393165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.
    McCarty MF; Wey J; Stoeltzing O; Liu W; Fan F; Bucana C; Mansfield PF; Ryan AJ; Ellis LM
    Mol Cancer Ther; 2004 Sep; 3(9):1041-8. PubMed ID: 15367698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
    Nicholson B; Gulding K; Conaway M; Wedge SR; Theodorescu D
    Clin Cancer Res; 2004 Dec; 10(24):8728-34. PubMed ID: 15623658
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.
    Ciardiello F; Caputo R; Damiano V; Caputo R; Troiani T; Vitagliano D; Carlomagno F; Veneziani BM; Fontanini G; Bianco AR; Tortora G
    Clin Cancer Res; 2003 Apr; 9(4):1546-56. PubMed ID: 12684431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.
    Wachsberger P; Burd R; Ryan A; Daskalakis C; Dicker AP
    Int J Radiat Oncol Biol Phys; 2009 Nov; 75(3):854-61. PubMed ID: 19801101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.
    Damiano V; Melisi D; Bianco C; Raben D; Caputo R; Fontanini G; Bianco R; Ryan A; Bianco AR; De Placido S; Ciardiello F; Tortora G
    Clin Cancer Res; 2005 Aug; 11(15):5639-44. PubMed ID: 16061883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.
    Yano S; Muguruma H; Matsumori Y; Goto H; Nakataki E; Edakuni N; Tomimoto H; Kakiuchi S; Yamamoto A; Uehara H; Ryan A; Sone S
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8789-98. PubMed ID: 16361567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
    Tuccillo C; Romano M; Troiani T; Martinelli E; Morgillo F; De Vita F; Bianco R; Fontanini G; Bianco RA; Tortora G; Ciardiello F
    Clin Cancer Res; 2005 Feb; 11(3):1268-76. PubMed ID: 15709198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
    Matsumori Y; Yano S; Goto H; Nakataki E; Wedge SR; Ryan AJ; Sone S
    Oncol Res; 2006; 16(1):15-26. PubMed ID: 16783964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.
    Shibuya K; Komaki R; Shintani T; Itasaka S; Ryan A; Jürgensmeier JM; Milas L; Ang K; Herbst RS; O'Reilly MS
    Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1534-43. PubMed ID: 17889445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The VEGFR Inhibitor Cediranib Improves the Efficacy of Fractionated Radiotherapy in a Colorectal Cancer Xenograft Model.
    Melsens E; Verberckmoes B; Rosseel N; Vanhove C; Descamps B; Pattyn P; Ceelen W
    Eur Surg Res; 2017; 58(3-4):95-108. PubMed ID: 28002822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.
    Wedge SR; Ogilvie DJ; Dukes M; Kendrew J; Chester R; Jackson JA; Boffey SJ; Valentine PJ; Curwen JO; Musgrove HL; Graham GA; Hughes GD; Thomas AP; Stokes ES; Curry B; Richmond GH; Wadsworth PF; Bigley AL; Hennequin LF
    Cancer Res; 2002 Aug; 62(16):4645-55. PubMed ID: 12183421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
    Frederick B; Gustafson D; Bianco C; Ciardiello F; Dimery I; Raben D
    Int J Radiat Oncol Biol Phys; 2006 Jan; 64(1):33-7. PubMed ID: 16377413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.
    Gustafson DL; Bradshaw-Pierce EL; Merz AL; Zirrolli JA
    J Pharmacol Exp Ther; 2006 Aug; 318(2):872-80. PubMed ID: 16644900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
    Ciardiello F; Bianco R; Caputo R; Caputo R; Damiano V; Troiani T; Melisi D; De Vita F; De Placido S; Bianco AR; Tortora G
    Clin Cancer Res; 2004 Jan; 10(2):784-93. PubMed ID: 14760102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.
    Wu W; Onn A; Isobe T; Itasaka S; Langley RR; Shitani T; Shibuya K; Komaki R; Ryan AJ; Fidler IJ; Herbst RS; O'Reilly MS
    Mol Cancer Ther; 2007 Feb; 6(2):471-83. PubMed ID: 17308046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.
    Beaudry P; Force J; Naumov GN; Wang A; Baker CH; Ryan A; Soker S; Johnson BE; Folkman J; Heymach JV
    Clin Cancer Res; 2005 May; 11(9):3514-22. PubMed ID: 15867254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation.
    Ning S; Laird D; Cherrington JM; Knox SJ
    Radiat Res; 2002 Jan; 157(1):45-51. PubMed ID: 11754641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.